Fig. 3: Post-exposure antibody therapy against SARS-CoV-2 variants in K18-hACE2 mice.
From: In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
a–f, Eight-to-ten-week-old female and male K18-hACE2 transgenic mice were administered 103 FFU of the SARS-CoV-2 N501Y/D614G (a–c) or Wash-B.1.351 (d–f) strains by intranasal inoculation. One day later, mice received 200 μg (about 10 mg kg−1) of the indicated mAb treatment by intraperitoneal injection. Tissues were collected at six days after infection. a, d, Weight change after infection with SARS-CoV-2 (mean ± s.e.m.; in order from left to right n = 15, 6, 6, 6, 6, 7 and 7 (a, d) mice per group, two experiments; one-way ANOVA with Dunnett’s test of area under the curve. NS, not significant, ****P < 0.0001). Viral RNA levels in the lung (b, e) and nasal wash (c, f) (line indicates median; in order from left to right n = 7, 6, 6, 6, 6, 7 and 7 (b); n = 9, 6, 6, 6, 6, 7 and 7 (c, e, f) mice per group, 2 experiments; one-way ANOVA with Dunnett’s test with comparison to control mAb. NS, not significant, ****P < 0.0001; **P = 0.0014 (left) and 0.0088 (right), ***P = 0.0007 (left) and 0.0003 (right) (b); **P = 0.0026 (left), 0.0041 (middle) and 0.0049 (right) (c); **P = 0.0049, ***P = 0.0004 (e); **P = 0.0094, ***P = 0.0005, *P = 0.0442 (f)). Dotted line indicates the limit of detection of the assay.
